Identity graph
Baxiva headquarters, locations and relationships
- Legal name
- Baxiva AG
- Industry
- Healthcare
- Founded
- 2025
- Website
- baxiva.com
- LinkedIn profile for Baxiva
Baxiva office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Zürich | Zurich | Switzerland | Headquarters |
- Parent company
- No parent company recorded in GraphIQ.ai.
Verified from public filings, company websites and news · Methodology
Open in GraphIQ.aiMore Baxiva data in GraphIQ.ai
This page shows the public record. Sign in with a work email to open the rest of the entity.
-
Technographics (available after sign-in)
Software, cloud and infrastructure in use.
-
Firmographics (available after sign-in)
Revenue, headcount, growth and industry codes.
-
Capabilities (available after sign-in)
Products, services and certifications.
-
News (available after sign-in)
Recent coverage and signals, resolved to the entity.
-
And more (available after sign-in)
Subsidiaries, people and lookalike companies.
Who uses the Baxiva entity
-
Revenue and GTM teams
Territories, enrichment and account expansion on one resolved account.
RevOps Sales & marketing -
Industry and supply chain
Suppliers, sites and partners mapped to the right legal entity.
Industry -
Private equity and investors
Corporate family, comparable companies and deal sourcing.
Private equity -
Government and public sector
Supplier vetting, ownership and jurisdiction checks against one verified entity.
Government -
Developers and AI agents
The entity and its relationships through the REST API and MCP server.
Developers
About Baxiva
Baxiva is headquartered in Zürich, Zurich, Switzerland. Founded in 2025, the company employs approximately 5 people worldwide.
Where is Baxiva's main office?
Baxiva's main headquarters office is located at 1 Wagistrasse, Zürich, Zurich 8952, Switzerland. This is the company's primary corporate address.
What does Baxiva do?
Baxiva is an emerging biotechnology startup focused on the development of next-generation glycoconjugate vaccines designed to prevent and combat bacterial infections. By leveraging advanced glycoengineering technologies and innovative vaccine platforms, Baxiva aims to create more effective and longer-lasting immunizations that address both existing and emerging bacterial threats.
One entity, every stage
Put Baxiva to work across your revenue bowtie
- Target Define the market Build the account list from companies shaped like your best customers, Baxiva included. Fingerprint search
- Cover Plan territories Baxiva resolves to one account, so it lands in one territory, once. Territory planning
- Engage Act on timing Leadership changes, funding and M&A arrive linked to the account, not a loose headline. Signal monitoring
- Convert Close on a resolved record Inbound and closed-won attach to one CRM record, with no duplicates to merge. CRM enrichment
- Retain Ground every answer Customer teams and AI agents answer from the same entity, with a source and a date. AI agent data layer
- Expand Find the next buyer inside Follow subsidiaries and divisions to the next team that can buy. Account expansion
About the source
What is GraphIQ.ai?
A B2B identity graph. It resolves each organization into one verified entity and maps its parent and subsidiaries, employees, competitors and news signals. Revenue teams use it in the product; AI agents query it through the REST API and MCP server.
POST/api/v2/organizations/search
Baxiva: frequently asked questions
Where is Baxiva headquarters?
1 Wagistrasse, Zürich, Zurich 8952, Switzerland.
When was Baxiva founded?
2025.
How many employees does Baxiva have?
About 5, as of October 2026 (GraphIQ.ai estimate).
Questions about GraphIQ.ai
Is GraphIQ.ai a list of companies like a spreadsheet?
No. Each organization resolves to one verified entity linked to its parent, subsidiaries, people and signals, so Baxiva here is the same Baxiva in your CRM, territory plan and agent answers.
Where does this Baxiva data come from?
Public filings, company websites and news, resolved to one entity and continuously updated.